Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Centessa Pharmaceuticals plc

If you’re looking for investment ideas right now, several top-rated Wall Street analysts (each with five-star ratings) believe that the following s...

These 3 Unknown Stocks Can Double, Say Five-Star Analysts – 12/11/2025

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Centessa Pharmaceuticals, with a price target of $62.00. Olson co...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CNTA	$26.51	-2.47%	2.41M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CNTA	$26.51	-2.5%	2.41M
3
4
5
6

CNTA

CNTA

Get Centessa Pharmaceuticals plc Data in Excel

Get Centessa Pharmaceuticals plc Data in Excel